Podcasts about AstraZeneca

Could studying the DNA of extinct animals – or even bringing them back to life – help us save today's endangered species and inform modern medicine?  That may sound like the premise for a Hollywood movie, but it's work that our Raise the Line guest, Dr. Beth Shapiro, is actually engaged in as Chief Science Officer at Colossal Biosciences, which describes itself as the world's first and only de-extinction company.  “It's not just about learning about the past. It's learning about the past so we have more validated scientific information that we can use to predict what we can do to better influence the future,” she tells host Michael Carrese. An internationally-renowned evolutionary molecular biologist and paleogeneticist, Dr. Shapiro is a pioneer in ancient DNA research and has successfully sequenced genomes, like that of the dodo, to study evolution and the impact on humans. At Colossal Biosciences, she leads teams working to bring back traits of extinct species such as the mammoth, not for spectacle, but to restore ecological balance. “When species become extinct, you lose really fundamental interactions between species that existed in that ecosystem. By taking a species that's alive today and editing its DNA so that it resembles those extinct species, we can functionally replace those missing ecological interactions.” Tune into this utterly fascinating conversation to hear about what Jurassic Park got wrong, the positive ecological impact of reintroducing giant tortoises to Mauritius, and the ethics of using gene editing and other biotechnologies. Mentioned in this episode:Colossal Biosciences If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Global markets stabilize following the valuation-fueled tech rout, though the outlook for A.I. adoption remains mixed. In the U.S., the Supreme Court is hearing arguments over the legality of President Trump's sweeping tariff agenda, with legal scholars split over the likely outcome. In the U.K., focus is back on the Bank of England ahead of today's rate decision, with analysts split over the path forward given the recent spate of weaker data. It's another busy day on the earnings front – Commerzbank reported a surprise fall in third quarter profit, though raised its revenue outlook with CEO Bettina Orlopp telling CNBC net interest income is improving. Meanwhile, the UK's most valuable company, AstraZeneca, reported a strong set of results, beating on revenue and EPS while reiterating its full year guidance.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

APAC stocks were higher as the region took impetus from the rebound on Wall St, where all major indices gained amid dip buying.European equity futures indicate an uneventful cash market open with Euro Stoxx 50 futures relatively flat after the cash market closed with gains of 0.2% on Wednesday.DXY traded rangebound after having recently snapped a 5-day rally, despite firmer-than-expected ADP and ISM Services data, while catalysts were quiet overnight10yr UST futures saw some slight reprieve after slumping yesterday; Bund futures languished near the prior day's lows.US President Trump is scheduled to make an announcement at 11:00EST/16:00GMT on Thursday.Looking ahead, highlights include German Industrial Production, EZ Retail Sales, Canadian Leading Index, US Chicago Fed Labour Market Indicators, US Challenger Layoffs, BoE, Banxico & Norges Bank Policy Announcements, Speakers including Fed's Williams, Barr, Hammack, Waller, Paulson & Musalem, ECB's Lane, Nagel, Schnabel & de Guindos, BoE's Bailey, BoC's Macklem, Rogers & Kozicki, Supply from Spain & FranceEarnings from Continental, Commerzbank, AstraZeneca, Sainsbury's, Airbnb, ConocoPhillips & Warner Bros.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

“The differentiator in our business isn't the equipment and the facility—it's the scientists working with customers to create assays and solve complex scientific challenges.”Leon Wyszkowski has spent nearly three decades in drug development, including 20 years at Thermo Fisher Scientific in roles spanning clinical services, CDMO operations, and now analytical services. His perspective on the evolution from internal pharma operations to service provider offers insights into how the industry's approach to outsourcing has matured.In this conversation, Leon discusses Thermo Fisher's expansion in the Nordics, the company's partnership with AstraZeneca's BioVenture Hub, and why trust remains the fundamental factor when biotechs and pharma companies evaluate analytical service partners.Read more.

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen?

Your morning briefing, the business news you need in just 15 minutes.On today's podcast:(1) Zohran Mamdani was elected the 111th mayor of New York in a historic victory that will put an avowed democratic socialist in charge of the city that serves as the capital of global finance.(2) The global selloff in semiconductor stocks accelerated on concern over lofty valuations for some of the artificial intelligence boom’s biggest winners.(3) UK Chancellor of the Exchequer Rachel Reeves will meet CEOs from top insurers in Downing Street on Wednesday, as she seeks to encourage more investment in the City ahead of a tricky budget later this month.(4) European Union member states clinched a preliminary deal to reduce emissions by 90% through 2040 compared with 1990 levels, a move that bolsters the bloc’s climate leadership credentials ahead of the COP30 summit.(5) WhatsApp, the popular messaging service owned by Meta Platforms Inc., introduced a standalone Apple Watch app that makes it easier for users to interact with their chats from Apple Inc.’s smartwatch without pulling out an iPhone.Podcast Conversation: I Saw a Vision of Chocolate’s Future in an Amsterdam BrownieSee omnystudio.com/listener for privacy information.

According to the Bloomberg School of Public Health at Johns Hopkins University, women make up 70% of the global healthcare workforce but hold only about 25% of leadership positions. Our guest today on Raise the Line, Dr. Roopa Dhatt, has been a leading voice in the movement to correct that imbalance through co-founding an organization called Women in Global Health (WGH), which has established chapters in over 60 countries since it started a decade ago. Dr. Dhatt is also pursuing that agenda and addressing other pressing issues in healthcare as a Young Global Leader at the World Economic Forum. “We're changing the equation so women delivering health are also viewed and valued as leaders,” says the internal medicine physician and assistant professor at Georgetown University School of Medicine. Beyond leadership equity, Dr. Dhatt is also seeking to address systemic pay inequities and high levels of violence and harassment experienced by women in the health sector, issues that were highlighted in research conducted by WGH. Although WGH has seen high-level success influencing policy at the World Health Organization and United Nations, Dr. Dhatt says the heart of its success is local. “Women community health workers have begun to see themselves as leaders and the heroines of health in their communities. That's profound change.” Join host Michael Carrese for a probing conversation that identifies the structural barriers blocking advancement for women and that explains why the health of communities and the planet depend on inclusive leadership.Mentioned in this episode:Women in Global HealthWHO Report: Delivered By Women, Led By MenDr. Roopa Dhatt on LinkedIn If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Danmark har Novo Nordisk, Sverige har AstraZeneca – hva har Norge? Vi ser på hvorfor norsk bioteknologi fortsatt er et uutnyttet potensial, og hvordan Radiumhospitalet likevel skaper selskaper i verdensklasse. Med Øystein Soug (Oncoinvent) og Erling Nordbø (Aleap Ventures) snakker vi om hvordan vi kunne ligget langt foran med politisk vilje og et veikart som faktisk følges.

"The value isn't in giving them the coffee beans and hoping they take that away and make a cup of coffee – what they need is a drink. So instead of giving them the data, do the extra steps and pull out the insights for them." - Satvinder Panesar, Data and Analytics Strategy Director, AstraZeneca Procurement leaders are surrounded by data, but turning numbers into true business impact is a new kind of challenge.  As AI and analytics tools promise even more information, the real differentiator is knowing how to interpret, validate, and act on those outputs… before your competitors do. Satvinder Panesar, Data and Analytics Strategy Director at AstraZeneca, joined Philip Ideson at ProcureTEX in London. Philip was there at the invitation of Beroe to speak with some of their customers about turning data into actionable insights. In this conversation, Sat breaks down the evolution of procurement analytics, explains why data literacy is a must-have skill, and points out how any leader or team can begin building those muscles, starting with the tools they already have. Expect a practical, honest conversation about the skills gap, the dangers of outsourcing data thinking, and how procurement teams can take charge in a world of increasingly complex analytics: Why "insights" matter more than raw data in procurement How to bridge gaps between data, category, and analytics teams  Practical first steps to improve procurement data literacy What AI can (and can't) do for procurement professionals Links: Satvinder Panesar on LinkedIn AOP Provider Directory: Beroe Subscribe to This Week in Procurement Subscribe to Art of Procurement on YouTube  

Avaluem les conseq

On Friday's Mark Levin Show, WJNO's Brian Mudd fills in for Mark. It's chilling that anti-American Senate Democrats voted against pay for military and essential workers amid the 31-day government shutdown. These Democrats are making them political pawns. President ​Trump ​is doing what he can - he ​ordered ​​all ​available ​funds ​to ​be ​identified ​and ​allocated ​to ​cover ​the ​$5.3 ​billion ​​payday. The average American hasn't felt this shutdown and Republican polling has surged during it. This ​is ​the ​second ​longest shutdown, ​closing ​in ​on ​those ​35 ​days ​of ​the ​longest ​that ​we ​had ​back ​in ​2019 ​during ​Trump's ​first ​term. ​You ​don't ​even ​remember ​that and 2019 was a great year. Later, two federal judges expect the Trump administration wave a magic wand and come up with money to pay SNAP, which expires Saturday. It's also chilling that Jack Smith weaponized the DOJ by issuing 197 subpoenas to 34 individuals and 163 businesses, targeting records of over 430 Republicans and entities creating an "enemies list.” This government overreach against political opposition is unsurprising after the Trump-Russia hoax and impeachments. Afterward, in the past 31 days, Trump has neutralized nearly a third of drug-running boats entering the US, secured $5 billion in tariffs and most-favored-nation status, negotiated AstraZeneca's prescription drug pricing to save Americans over $15 billion annually while attracting $50 billion in domestic R&D investments, finalized a Chinese trade deal ending the US soybean embargo and promising a fentanyl crackdown, and lifted the estimated economic growth rate to 3.9% per the Atlanta Fed GDP tracker. What have the Democrats done? Learn more about your ad choices. Visit podcastchoices.com/adchoices

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/EVZ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 29, 2026.Making Precision Decisions for Patients With EGFRm NSCLC: Success Strategies With Targeted Options, Potent Combinations, and Emerging Agents In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

“They say it takes a village to raise a child. I really think it takes a village to treat a patient,” says Dr. Lanae Mullane, a naturopathic doctor and clinical strategist who has spent years at the forefront of bridging functional medicine, nutraceutical development, and digital health. In this episode of Raise the Line, host Lindsey Smith explores Dr. Mullane's view that naturopathic medicine complements conventional care by expanding -- not replacing -- the clinical toolkit, and that collaboration should be the future of medicine. “At the end of the day, collaboration and connection create the best outcomes for the people we serve,” she says. Their in-depth conversation also spans the shifting landscape of women's hormone health, including the perimenopausal transition and long-overdue calls for research equity. “We're not just smaller versions of men. We need to have dedicated research for us.” Tune in to learn about the importance of grounding health in sustainable habits, rethinking midlife care for women, and how to help patients take ownership of their health.Mentioned in this episode:Joi + BlokesSuppCoDr. Mullane's Clinical Website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

El presupuesto para becas crece, pero baja el de educación superior, panistas destacados se dividen sobre el fin de las alianzas con otros partidos y el aeropuerto de Tulum pierde altura por la desaceleración turística, con Puri Lucena y Ari Ortega.-> ¿La viste o lo leíste?: Novela negra y misterio00:00 Introducción02:39 El presupuesto para becas aumenta, pero disminuye en educación superior06:54 Panistas destacados dividen opinión sobre el fin de las alianzas rumbo al 202712:36 Estados Unidos revoca 13 rutas aéreas de México y congela la expansión en el AICM y el AIFA16:04 México se quedó atrás en la carrera de los coches eléctricos y acelera como mercado de híbridos19:37 México es el laboratorio tecnológico detrás de la medicina de AstraZeneca

Le président américain veut aligner les prix des médicaments aux États-Unis sur les plus bas pratiqués dans le monde.Un plan qui pourrait soulager les patients américains, mais peser lourd sur le portefeuille et l'accès aux traitements des Européens. Donald Trump justifie sa politique par un constat : les prix des médicaments aux États-Unis sont en moyenne plus de quatre fois supérieurs à ceux pratiqués dans les autres pays développés, selon la Rand Corporation, un institut de recherche américain. Cette différence s'explique par l'absence de régulation nationale. Les laboratoires fixent librement leurs tarifs, et les compagnies d'assurance privées négocient ensuite les remboursements, souvent sans réel pouvoir de contrainte. Résultat, les traitements sont vendus beaucoup plus chers qu'en Europe, où les prix sont encadrés par les autorités publiques. Pour corriger cette distorsion, Donald Trump veut désormais que les prix américains soient alignés sur les plus bas tarifs pratiqués à l'étranger. Une réforme qui, sur le papier, paraît bénéfique pour les patients américains. Mais dans les faits, elle risque de bouleverser tout l'équilibre mondial de l'industrie pharmaceutique. À lire aussiLes États-Unis piégés par leur dépendance aux médicaments indiens? Un effet de vase communicant : les laboratoires pourraient se détourner de l'Europe Le problème, c'est que le marché américain représente à lui seul la principale source de revenus des grands groupes pharmaceutiques. Si les prix baissent aux États-Unis, les laboratoires verront leurs marges chuter sur leur marché principal. Et pour compenser, ils pourraient relever leurs prix en Europe ou retarder la mise sur le marché de nouveaux traitements. Certains géants du secteur, comme Pfizer ou AstraZeneca, ont déjà annoncé revoir leurs stratégies de commercialisation sur le Vieux Continent. D'autres entreprises hésitent même à s'y implanter, ou exigent désormais davantage de contrôle dans les négociations de prix avec les autorités de santé. L'Europe, où les tarifs sont encadrés pays par pays et souvent bien plus bas qu'ailleurs, risque ainsi de devenir un marché secondaire pour les géants de la pharma. Un paradoxe pour un continent qui cherche justement à rester attractif et innovant dans le domaine de la santé. À lire aussiComment l'Union européenne compte éviter les pénuries de médicaments? Souveraineté pharmaceutique, un défi plus que jamais stratégique pour l'Europe Face à cette situation, Bruxelles reste prudente. La Commission européenne dit suivre de près l'évolution du dossier américain. Mais cette tension arrive à un moment charnière : l'Union révise actuellement sa législation pharmaceutique, en vigueur depuis 2004, afin de renforcer la compétitivité du secteur et réduire la dépendance aux importations. Depuis la pandémie de Covid-19, les Vingt-Sept ont pris conscience de leur fragilité : les principes actifs viennent majoritairement d'Asie, et une partie de l'innovation pharmaceutique dépend encore largement des États-Unis. Or, la politique actuelle de Donald Trump, en poussant à la relocalisation et à la défense des intérêts américains, risque d'accentuer cette dépendance européenne. La véritable question est donc celle-ci : qui paiera le prix de cette nouvelle guerre du médicament ? L'Europe, en acceptant de payer plus cher pour conserver l'accès à l'innovation ? Ou bien le monde pharmaceutique lui-même, s'il finit, à force de logique de court terme, par étouffer l'innovation et la coopération internationale ?

Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That's the second biggest buy of the year after Johnson & Johnson's January acquisition of Intra-Cellular. The Avidity buy could read through positively to Dyne Therapeutics, as both are aiming to treat neuromuscular ailments with RNA-targeting therapies. Dyne shares have nearly doubled over the past month, jumping approximately 40% after Novartis' news dropped.  The Avidity deal is the latest in an uptick on the pharma M&A front. Also this week, Eli Lilly doubled down on gene therapy with a pick up of Adverum Biotechnologies and its lead program for wet age-related macular degeneration. And Roche, which last month acquired 89bio in a $3.5 billion deal centered on a MASH candidate, said in its third-quarter earnings call on Thursday that more deals could be in the future. Finally, beyond the big guys, Leerink Partners predicts which small- to mid-cap firms might also be on the hunt for new pipeline goodies.  Following the dealmaking news, Novartis held its earning call on Tuesday. CEO Vas Narasimhan downplayed the deals Pfizer, AstraZeneca and Amgen have made with the White House, saying they don't address the root of the drug pricing problem President Donald Trump hopes to solve.   On other earnings calls, BioMarin announced plans to divest the hemophilia gene therapy Roctavian. Regeneron faced further questions about Eylea and issues with the Catalent plant that's been tripping up its regulatory applications. But the company didn't address last week's news that it was dropping a CAR T asset picked up from 2seventy bio. These are but two of the latest examples of underperforming assets in the cell and gene therapy space.  BridgeBio had positive news for patients with limb-girdle muscular dystrophy this week after acing a Phase III trial for an investigational substrate supplementation therapy. Analysts predict the asset could be before the FDA later this year or early next.   Finally, with the U.S. government shutdown going on a month, BioSpace takes a look at how the FDA is operating. 

“It's kind of a miracle, frankly,” says Dr. John Buse, a distinguished professor at the University of North Carolina School of Medicine, referring to the effectiveness of GLP-1 receptor agonist medications such as Ozempic in treating type 2 diabetes, promoting significant weight loss, and reducing cardiovascular risk. As a physician scientist for the last three decades at UNC, Dr. Buse has played a key role in ushering in this new era of diabetes care, leading or participating in over 200 clinical studies on this class of drugs and others. “Nothing has impacted diabetes care like the GLP-1 receptor agonists. I have lots of patients whose diabetes was never well controlled who have seen all their metabolic problems essentially resolved.”  In this fascinating conversation with Raise the Line host Lindsey Smith, Dr. Buse not only explains how these drugs work, but also provides a clear-eyed look at side effects, and addresses issues of cost and access. Join us for the remarkable story – including the role played by Gila monsters -- behind one of the biggest developments in medicine over the past several years from a world renowned diabetes researcher and clinician. Mentioned in this episode:UNC School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Amit Zavery, President, Chief Product Officer, and Chief Operating Officer at ServiceNow, sits down to talk with Bob Evans in this special episode of Cloud Wars Live. They dive deep into how ServiceNow's AI Experience is transforming enterprise workflows through automation, governance, and personalization. Zavery outlines a bold vision for delivering real ROI and trusted AI at scale.Reimagining Workflow with AI Experience The Big Themes:ServiceNow's AI Experience Is About Unified, Actionable Intelligence: Amit Zavery describes ServiceNow's AI Experience as more than a conversational interface, it's an orchestrated, end-to-end workflow platform that integrates voice, text, image recognition, agents, and enterprise systems. It's designed to eliminate the “spare part world” of fragmented tools and disconnected apps. By delivering one multimodal, multilingual interface, ServiceNow enables users to not just find information, but actually complete tasks and workflows.AI Governance and Control Are Built In, Not Bolted On: The AI Control Tower is ServiceNow's answer to one of the biggest enterprise challenges: AI governance. With this feature, companies can discover, monitor, and manage all AI usage, not only from ServiceNow but across third-party systems, too. CIOs and CISOs gain the ability to track who is using what AI systems, what agents are doing, and what data is being accessed.Industry-Specific Use Cases Drive Real-World AI Value: Enterprise AI Zavery says must be contextual, curated, and tightly integrated with business processes. ServiceNow is collaborating with customers like AstraZeneca (pharma), BT (telecom), and Rossmann (retail) to deploy agentic AI that delivers real value in vertical-specific environments. These aren't generic AI chatbots; they're intelligent agents embedded in workflows that help store managers order inventory, researchers manage supply chains, and employees navigate complex rules.The Big Quote: “I call it the spare part world we are in right now, and it's a very difficult thing for a lot of the leaders to really keep up with it. One to know, what are you using? How are you using it? What is the ROI on it? What are the costs associated with that?” Visit Cloud Wars for more.

In this episode, we dive into how advisory boards can be a game-changer for small businesses with Barbara Taylor and Ed Henkler . Unlike corporate boards, these groups are built on relationships and connections—bringing together people who share their expertise, networks, and insights to help a business grow. We'll discuss how to form an advisory board, the role connections play in bringing the right people to the table, and the impact these relationships can have on guiding strategy, opening doors, and creating new opportunities. If you're a small business owner looking for guidance, or a professional considering how your network could make a difference, this episode shows how advisory boards turn connections into lasting business growth.Barbara Taylor, CPCU, offers 20+ years of expertise in business coaching, talent management leadership development and performance management. Barbara has built a reputation for designing creative leadership development programs.She has designed and implemented effective talent management strategies for numerous Fortune 500 clients including L'Oreal, Comcast, GlaxoSmithKline, AstraZeneca, L3, Goodwill and The Kellogg Company.Currently, Barbara is a business partner of JanBara & Associates, a coaching and executive development firm specializing in accelerating the performance of people and organizations. The JanBara partners believe that purposeful human performance is the greatest contributing factor to a company's success. Barbara has co-created two leading-edge leadership programs: Silo-Busting Networking and Strategic Thinking for Middle Managers.Ed Henkler is a social entrepreneur who is passionate about improving the quality of life and employability of people who are blind or visually-impaired. He believes there is a business ROI to hire people with disabilities. He is working with several veteran-owned businesses which focus on increasing the meaningful employment of veterans, military spouses, and people with disabilities.Music by: ⁠⁠⁠⁠jorikbasov⁠⁠⁠⁠ from ⁠⁠⁠⁠Pixabay⁠⁠⁠⁠Contact InformationBarbara Taylor- btaylor@janbara.comEd Henkler- edhenkler@theblindguide.com or theblindguide.comBenny Carreon- Velocity Technology Group- benny@velocitytechnology.groupDennis Jackson-WorX Solution- dennisj@worxsolution.com

Línea Directa anuncia su seguro de hogar. En 'Buenos días, Javi y Mar', José Real comenta la bajada de temperaturas y el cambio de horario a invierno. Se informa sobre una vigilia en Paiporta y la protesta por la dimisión de Mazón, además de la reunión de Puigdemont y Junts en Perpignan. Se detiene a dos sospechosos de un robo en Francia y se celebran los Premios Princesa de Asturias, donde el discurso de Leonor genera controversia. Fernando Martín habla sobre cosas que pierden su encanto, como ciertas apps, Facebook o la máquina de zumos, y cómo antes las cosas emocionaban más. Se presenta una historia ficticia donde un hombre es detenido al entregar una cartera perdida, ya que era un delincuente buscado. Se publicita Oro Bailén, Loterías de la ONCE, AstraZeneca, una campaña de seguridad vial, Chocolates Valor y Antaño Rioja. Se habla de un tejido inteligente que puede escuchar, responder y comunicarse con otros dispositivos, ejemplificando con una camiseta que expresa emociones o ...

Doença genética rara, a amiloidose por transtirretina hereditária (ATTRv) é causada por alterações no gene TTR, responsável pela produção da proteína transtirretina.Por ser uma condição pouco conhecida, pode ser confundida com outras doenças, o que atrasa o diagnóstico e o início do tratamento adequado. Esse atraso, por sua vez, pode impactar diretamente a qualidade de vida dos pacientes.Neste episódio do DrauzioCast, o dr. Drauzio Varella conversa com o neurologista dr. Marcondes Cavalcante França Jr. e com o paciente Jorge Luiz Neves sobre como a ATTRv se manifesta e quais sinais precoces merecem atenção.Conteúdo produzido em parceria com a Astrazeneca.BR-45866. Material destinado a todos os públicos. Aprovado em Outubro/2025Veja também: SHUa: o que é ser diagnosticado com uma doença rara?

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMX865. CME/MOC/EBAH/AAPA/IPCE credit will be available until October 13, 2026.The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMX865. CME/MOC/EBAH/AAPA/IPCE credit will be available until October 13, 2026.The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

“We were able to show multiple datasets that actually deliver against this vision that antibody drug conjugates can improve on and therefore displace chemotherapy” says Dr. Susan Galbraith, AstraZeneca’s EVP of oncology R&D. Galbraith joins Bloomberg Intelligence analyst Sam Fazeli to break down key findings from ESMO — from early-line HER2 breast cancer data to progress in bladder and lung cancer. She details the promise of Enhertu and Datopotamab, AstraZeneca’s antibody-drug conjugates (ADCs), and how their work may transform cancer treatment in curative settings.See omnystudio.com/listener for privacy information.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMX865. CME/MOC/EBAH/AAPA/IPCE credit will be available until October 13, 2026.The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMX865. CME/MOC/EBAH/AAPA/IPCE credit will be available until October 13, 2026.The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMX865. CME/MOC/EBAH/AAPA/IPCE credit will be available until October 13, 2026.The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMX865. CME/MOC/EBAH/AAPA/IPCE credit will be available until October 13, 2026.The Clock Strikes Innovation in CLL: Upfront Care With Newer, Time-Limited BTKi Combinations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving deep into a series of significant events that are shaping the future of drug development and patient care.Starting with Merck KGaA, their decision to close the Active Pharmaceutical Ingredient plant in Arklow, Ireland by 2028 marks a pivotal shift in their manufacturing strategy. This move follows a strategic review and is emblematic of broader industry trends where companies reassess their operational strategies for greater efficiency. While this decision may impact the local workforce and supply chain dynamics, it underscores a wider reevaluation within the industry regarding sourcing strategies and optimizing production capabilities.Turning to regulatory news, Amgen and AstraZeneca have achieved a notable milestone with Tezspire, which has received approval for a second indication in both the U.S. and Europe. This success highlights the strategic importance of expanding drug indications to maximize therapeutic potential and market reach. The approval also reflects a trend where robust clinical data supports regulatory endorsements across various regions, enhancing the global footprint of pharmaceutical innovations.In manufacturing developments, Galderma is making headlines with a $650 million investment in U.S.-based production facilities for Nemluvio. This commitment to domestic manufacturing aligns with industry-wide movements towards reshoring production to bolster supply chain resilience. As demand for dermatological products increases, enhancing local infrastructure promises not only to meet market needs but also to secure supply stability in uncertain times.Meanwhile, Moderna's recent decision to discontinue its congenital cytomegalovirus vaccine program after disappointing Phase 3 results illustrates the inherent uncertainties present in vaccine development. Despite extensive efforts, the vaccine did not demonstrate sufficient efficacy in preventing CMV infections among women. This outcome serves as a reminder of the critical role that robust clinical trial data plays in guiding strategic decisions within pharmaceutical pipelines. While mRNA technology has seen success against COVID-19, this setback highlights complexities involved when tackling other viral pathogens, potentially redirecting Moderna's focus towards more promising candidates.Roche is navigating through challenges such as currency fluctuations and slower-than-expected pharmaceutical sales in its third quarter. Despite these headwinds, Roche projects confidence in its long-term growth strategies, showcasing resilience through its diversified portfolio. Furthermore, Roche's decision to discontinue five Chugai solid tumor assets reflects broader industry movements towards reassessment and realignment within pipelines. Such decisions often emerge from early-phase trials failing to meet expected outcomes or shifts towards areas with greater promise, enabling companies like Roche to streamline resources towards more viable therapeutic areas.Compliance remains under scrutiny at Nephron Pharmaceuticals as ongoing FDA issues emphasize the necessity of maintaining stringent quality standards throughout manufacturing processes. Such regulatory challenges highlight the criticality of ensuring product safety and efficacy within the industry.On the technological front, the integration of artificial intelligence into life sciences commercialization is transforming industry landscapes. Though many organizations are still catching up with this digital shift, those that have embraced AI are experiencing significant improvements in efficiency and patient engagement. As companies continue embedding AI into their strategic frameworks, these initiatives promise to redefine operational paradigms and open new paths for growth.The landscape remains dynaSupport the show

“It wasn't a profession, it was a way of life,” observes internationally respected psychiatrist Dr. Nasser Loza, reflecting on a century-long family legacy in mental health care that began when his grandfather founded The Behman Hospital in Cairo. In this candid Raise the Line conversation with host Michael Carrese, Dr. Loza traces the transformation of psychiatry he's witnessed in his long career as increases in classifications, payment bureaucracy, reliance on pharmaceuticals, and technological disruption have each left their mark. The cumulative costs associated with these changes have, he laments, pushed care out of reach for many and hindered the human connection that is key to the discipline. He describes his prescription for countering these trends as a focus on effective and modest aims. “Rather than saying, come and see me in therapy for five years and I will make a better person out of you, I think focusing on symptom-targeted help is going to be what is needed.”  In this wide-ranging interview, you'll also learn about progress on advancing the rights of mental health patients and lowering stigmas, how to manage the rise of online therapy and use of AI chatbots, and the importance of empathy and transparency in mental health counseling. Don't miss this valuable perspective on a critically important dimension of healthcare that's informed by decades of experience as a clinician, government official and global advocate. Mentioned in this episode:The Behman HospitalMaadi Psychology Center If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Living with constant congestion, facial pressure, or a loss of smell can make daily life exhausting. For many people, these symptoms are more than just allergies or a lingering cold. They may be signs of chronic rhinosinusitis with nasal polyps (CRSwNP). Dr. Rohit Katial joins Kortney and Dr. G to unpack what CRSwNP really is, how it develops, and why type 2 inflammation plays such a key role. Together, they explain what's happening inside the sinuses, what symptoms to look for, and when it's time to see a specialist. What we cover about CRSwNP: What CRSwNP means: Chronic rhinosinusitis with nasal polyps is long-term inflammation of the nose and sinuses that lasts 12 weeks or more. What nasal polyps are: Soft, fluid-filled sacs (often “grape” or “pea” sized) that block airflow and lead to congestion and smell loss. Why it happens: Type 2 inflammation drives CRSwNP. Immune messengers like IL-4, IL-5, and IL-13 cause swelling and fluid buildup in the nasal lining. Who it affects: CRSwNP often overlaps with asthma, allergies, or aspirin sensitivity (AERD or Samter's Triad), making symptoms worse. When to seek help: If congestion, pressure, or loss of smell lasts more than 12 weeks, see an allergist or an ENT specialist. Early care can prevent sinus damage and improve breathing and quality of life. More episodes to support CRSwNP Ep. 101: What is Type 2 Inflammation? Ep. 102: Comorbidities of Type 2 Inflammation -  Connecting the Dots Between Multiple Allergic Conditions Ep. 109: Tezepelumab & Nasal Polyps - Inside the WAYPOINT Phase III Trial ___ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests:  Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

With the 2025-26 NHL season underway, the Florida Panthers have set out to accomplish a three-peat.Meanwhile, AstraZeneca has another goal in mind.The British pharma giant is continuing with its decades-long Get Body Checked Against Cancer campaign.With the assistance of agency partner Grey Health, AstraZeneca is on an ongoing quest to eradicate the stigma around getting screened for cancer and ignite a passion among fans to take a more proactive approach to their health. During Advertising Week, reporter Heerea Rikhraj moderated a panel with two leaders from Grey Health – chief creative officer Bruno Rebelo and planning director Astrid Kramm – about the latest iteration of the campaign and how effective it has been in terms of boosting cancer screening rates.For this week's podcast, Heerea reconnects with Bruno and Astrid about what else the agency has in the pipeline to support AstraZeneca throughout the season.And for our Trends segment, we're talking about how OpenAI's social media app Sora could disrupt medical marketing.Music: “Deep Reflection” by DP and Triple Scoop Music. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

This Day in Legal History: Abrams v. United States ArguedOn October 21, 1919, the U.S. Supreme Court heard arguments in Abrams v. United States, a seminal case in the development of First Amendment jurisprudence. The case arose during the post–World War I Red Scare, when the government aggressively prosecuted speech perceived as dangerous or subversive. The defendants were Russian immigrants who distributed leaflets in New York City denouncing U.S. military intervention in the Russian Revolution and calling for a general strike. They were charged and convicted under the Sedition Act of 1918 for allegedly inciting resistance to the war effort.The Supreme Court upheld their convictions in a 7–2 decision, finding that the speech posed a “clear and present danger” to national security. However, it was Justice Oliver Wendell Holmes' dissent, joined by Justice Louis Brandeis, that left the most lasting impression. Holmes argued that only speech intended to produce imminent lawless action should be punished, introducing the enduring metaphor of the “marketplace of ideas” as essential to democratic deliberation.Legally, the case illustrates the government's ability to impose post-speech punishment—penalties after speech has occurred—as opposed to prior restraint, which involves preventing speech before it happens. The distinction is vital in American law: prior restraints are almost always unconstitutional, while post-speech sanctions may be permitted under narrow circumstances. In Abrams, the Court leaned toward deference to governmental wartime authority, but Holmes' dissent marked the beginning of a shift toward greater speech protections.The decision laid the groundwork for the more speech-protective standards adopted in later cases such as Brandenburg v. Ohio (1969). The post-speech punishment principle debated in Abrams remains a cornerstone of First Amendment law, highlighting the tension between state interests and individual liberties in times of political conflict.When two alleged drug traffickers survived a U.S. military strike in the Caribbean, the Trump administration immediately repatriated them rather than detain them — a decision that reveals a troubling logic behind the president's new “war” on narco‑terrorism. The administration has declared the campaign a “non‑international armed conflict,” but legal experts note that this classification offers no real authority for military detention. In other words, the United States can kill suspects under this self‑declared war framework, but it has no clear legal footing to hold survivors.Experts said the administration likely chose the least damaging option: send the survivors home and avoid a courtroom. Detaining them at Guantanamo or on U.S. soil would have triggered habeas corpus challenges, forced disclosure of evidence, and risked exposing the strikes as legally indefensible. One former State Department lawyer said any trial would have “undermined the narrative” that the attacks were lawful military operations. By refusing to hold prisoners, the administration sidesteps both judicial scrutiny and transparency.The result is a perverse incentive structure. If survivors are released but detainees are liabilities, the easiest path for officials is to ensure there are no survivors at all. The legal asymmetry—where killing is simpler than capture—encourages tactics that maximize lethality while minimizing accountability. As a result, Trump's “drug war” risks becoming less about law enforcement and more about ensuring that no one lives long enough to challenge the legality of U.S. actions.In Trump's drug war, prisoners may be too much of a legal headache, experts say | ReutersGlobal pharmaceutical companies are rapidly ramping up U.S. manufacturing in response to a looming Trump administration policy that would impose 100% tariffs on imported branded and patented drugs. While enforcement is delayed for companies that commit to domestic investment, the threat has already triggered a wave of fast-tracked spending, direct-to-consumer sales shifts, and pricing concessions in exchange for temporary tariff exemptions.Major players like Pfizer, AstraZeneca, Merck, Johnson & Johnson, Eli Lilly, and Roche have pledged tens of billions of dollars to build or expand plants across the U.S. to shield themselves from future penalties. Some, like Pfizer and AstraZeneca, secured multi-year tariff exemptions by agreeing to pricing deals and participation in the administration's new TrumpRx.gov program. Others, like Novartis and Sanofi, are spreading investments across multiple states and sites, creating thousands of jobs as part of their strategic insulation.The tariff threat is driving a major reshaping of global supply chains and investment strategies, as companies aim to avoid the legal and financial burden of import duties by domesticating both manufacturing and distribution. While some firms say they are already well-positioned with sufficient U.S. inventory, the broader trend reflects a defensive industry-wide shift to preemptively comply with the administration's protectionist push.Global drugmakers rush to boost US presence as tariff threat looms | ReutersTrevor Milton, the disgraced founder of electric-truck startup Nikola, is somehow back as a CEO—this time leading SyberJet Aircraft, a private jet manufacturer, according to reporting by Techdirt. Milton was convicted of fraud for deceiving investors about Nikola's technology, most famously releasing a misleading video of a prototype truck that was actually rolling downhill, not self-propelled. He was sentenced to four years in prison but never served a day, thanks to a pardon from Donald Trump earlier this year—reportedly after donating millions to Trump-aligned causes and hiring the brother of current Attorney General Pam Bondi as his attorney.Now, just months after that pardon, Milton has been tapped to lead development of a new high-speed jet for SyberJet, with promised performance metrics that already sound suspiciously ambitious. The company, privately backed, won't need to answer to public shareholders—but it will still need investor trust to raise money for a jet not slated for delivery until 2032. TechDirt points out how the company's promotional material leans into rewriting Milton's history, calling him “renowned” rather than acknowledging the full scope of his fraudulent past.The piece underscores a broader theme of “failing upward,” highlighting how white-collar offenders, especially white men with political connections, often land on their feet despite serious criminal convictions–and has some interesting implications for the future career of George Santos. Milton's quick rebound from federal fraud conviction to C-suite leadership is less an exception than a reminder of how accountability gaps persist in American corporate culture.Convicted Fraudster Trevor Milton Rides His Trump Pardon To Another CEO Job, Somehow | TechdirtIn my column for Bloomberg this week, I dive in to the governor's race in my home state. The 2025 New Jersey gubernatorial race has become a tax-policy showdown between Jack Ciattarelli and Mikie Sherrill—both of whom are framing affordability as their central mission, but doing so with deeply flawed approaches. Ciattarelli is offering aggressive tax cuts and structural overhauls that are, frankly, reckless in a state with a delicate and complicated fiscal ecosystem. His plan to flatten income tax brackets and slash corporate rates isn't just optimistic—it's ahistorical. We've seen this movie before in Kansas, where sweeping tax cuts led to revenue collapse, credit downgrades, and bipartisan regret. Ciattarelli is essentially proposing a rerun, but with no clearer escape plan if it fails.Sherrill, by contrast, is pragmatic to the point of inertia. Her emphasis on municipal service sharing and administrative tweaks is fine as far as it goes—but it doesn't go very far. Her promise to freeze utility rates via emergency powers, for instance, isn't just legally questionable, it also misdiagnoses the issue: state governments don't control wholesale energy prices. It's a symbolic gesture dressed up as policy.Neither candidate seems willing to address the structural drivers of New Jersey's notoriously high property taxes, preferring instead to nibble around the edges or promise caps that could backfire. That's a missed opportunity. As I argue in the column, New Jersey doesn't need sweeping cuts or more bureaucratic tinkering—it needs targeted relief for the people who actually feel the pinch. Expanding the state Earned Income Tax Credit and implementing a robust child tax credit would offer immediate, evidence-backed help to those struggling most with affordability. These aren't radical ideas; they're already working in other states.Ciattarelli's plan is built on trickle-down economics and wishful math. Sherrill's is built on competent management, but lacks ambition. The voters deserve more than either of those options.Tax Platforms in NJ Governor's Race Leave Out the Best Ideas This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving Trop2-targeted therapies. This reflects the increasing focus on antibody-drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy.In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R&D capabilities in the U.S. Such strategic investments are crucial for maintaining competitive advantage and ensuring drug availability while meeting rising demands and streamlining supply chains.Turning to regulatory updates, the FDA has approved Amgen and AstraZeneca's Tezspire for chronic rhinosinusitis with nasal polyps. This marks Tezspire's second indication, following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent.In oncology, Merck's Keytruda and Astellas/Pfizer's Padcev have made headlines with compelling results in muscle-invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes.Roche has expanded the indication of its aging oncology drug Gazyva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Gazyva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas.AstraZeneca and Daiichi Sankyo's Enhertu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis' Pluvicto demonstrated promise in slowing hormone-sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology.However, not all developments have been positive. AstraZeneca faced setbacks when its Imfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the FDA.The industry is also witnessing significant advancements in next-generation ADCs, as evidenced by Tubulis' 59% response rate in early clinical trials, which has attracted substantial investor interest. Additionally, Grail's Galleri cancer blood test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices.These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences' $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development, which remains a focal point for innovative cancer therapies.Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors characterized by signSupport the show

The I Love CVille Show headlines: UVA Snatches Win From WSU; Hoos #16 In Nation AstraZeneca 600 New Jobs Will Be $125K Avg Salary Is The New Zoning Ordinance Lawsuit All Done? Will 303 Alderman Rd Turn Back Into Brownstones? UVA Interim Prez Claps Back At Trump Administration Thousands Gather For “No Kings” Protest In AlbCo Will This Election Cycle Impact AlbCo & City Schools? If You Need CVille Office Space, Contact Jerry Miller Read Viewer & Listener Comments Live On-Air The I Love CVille Show airs live Monday – Friday from 12:30 pm – 1:30 pm on The I Love CVille Network. Watch and listen to The I Love CVille Show on Facebook, Instagram, Twitter, LinkedIn, iTunes, Apple Podcast, YouTube, Spotify, Fountain, Amazon Music, Audible, Rumble and iLoveCVille.com.

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs discuss the reasons US Food and Drug Administration Commissioner Martin Makary could have helped negotiate the Most Favored Nation drug pricing deal with Astra Zeneca (:30) and the deal's potential impact on the 340B program (16:35). They also consider the Justice Department's alternative interpretation of off-label promotion regulations and the effect on the scientific exchange of information about drugs (19:16). More On These Topics From The Pink Sheet US FDA Commissioner's Involvement In AstraZeneca Pricing Deal Raises Ethical, Legal Questions: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/us-fda-commissioners-involvement-in-astrazeneca-pricing-deal-raises-ethical-legal-questions-IJV4LMTDA5E65KCOFQUQM76GCA/ EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/emd-serono-ivf-candidate-among-first-us-fda-priority-voucher-recipients-as-part-of-mfn-deal-LKHA6VRTKRE6DJERGNCWCGMBF4/ Manufacturer Most Favored Nation Deals: How They Could Be Protected From 340B: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/manufacturer-most-favored-nation-deals-how-they-could-be-protected-from-340b-FALSG7GHM5GQBFN3I5SPERJIYU/ Off-Label Promotion: DOJ May Take New Look At Scientific Information Exchange: https://insights.citeline.com/pink-sheet/legalandip/litigation/off-label-promotion-doj-may-take-new-look-at-scientific-information-exchange-R62PQJFQTRBCVGCZE57GWM3Q3Q/

Discounted prices will be offered at TrumpRx – a new direct-to-consumer website launching next year. It's a result of deals President Trump recently cut with pharmaceutical giants like Pfizer and AstraZeneca. But who really benefits?

“Giving learners options gives them a better learning experience. It's more holistic and more comprehensive,” says Sean Moloney, CEO and founder of EmbodyXR, an extended reality platform focused on the use of immersive technologies in medical education. In this eye-opening Raise the Line conversation, Moloney explains how AI-powered extended reality (XR) --which integrates augmented, virtual, and simulation-based environments -- allows learners to interact with patients, explore multiple diagnostic choices, and experience varied outcomes based on their decisions. The result, he notes, is not only stronger engagement in learning, but a measurable improvement in understanding. Despite these gains, Moloney is quick to point out that he sees these technologies as complements to traditional training, not substitutes for it. “We'll never replace in-person teaching,” he says, “but we can make learners even better.” Beyond training future clinicians, the EmbodyXR platform is also offering new modes of patient and caregiver education, such as augmented reality guidance for using medical devices at home. Join host Lindsey Smith as she explores how EmbodyXR achieves and maintains clinical accuracy, the connectivity it offers between headsets, personal computers and mobile devices, and other capabilities that are shaping the future of how healthcare professionals and patients will learn. Mentioned in this episode:EmbodyXR If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

El programa 'Buenos días, Javi y Mar' presenta la mejor variedad musical. Se escucha una 'Noite Ochentera' y diversas canciones en español e inglés. Ed Sheeran tendrá su logo en la camiseta del FC Barcelona. HSN ofrece complementos naturales para las defensas y Moove celebra un ahorro en repostaje. Security Direct protege el hogar con alarma inteligente y SPOTICAR regala hasta tres años de garantía en coches de ocasión. El Ministerio de Cultura es el punto de encuentro y ONCE comparte su ilusión. Opel Corsa ofrece condiciones excepcionales y 'Pro de Citroën' brinda financiación y ofertas exclusivas. Peugeot Service es el mejor profesional para el coche, mientras AstraZeneca investiga el cáncer de mama. MAPFRE ofrece soluciones financieras y ALDI vende frutas y verduras a buen precio. Se pueden conseguir smartphones Xiaomi gratis con fibra. La banda Marea interpreta 'Contigo' y Andy & Lucas cantan 'Manéjando por las Calles'. Miley Cyrus canta 'Wrecking Ball' y La Quinta Estación 'El ...

Taylor Swift es imparable, su álbum "Midnights" es el vinilo más vendido de la década en el Reino Unido. En la última edición del Record Store Day, hubo lanzamientos exclusivos con iniciativas sostenibles como el reciclaje de vinilos. Dua Lipa ha sacado el título oficial de español y está muy contenta. Habla un español considerablemente bueno. En CADENA 100 hay más talento, como el de HSN, que refuerza las defensas con complementos naturales. El nuevo Jeep Avenger 4xe es ideal para ver el mundo desde un nuevo ángulo. Octubre es el mes de concienciación del cáncer de mama, y AstraZeneca investiga con la ambición de transformar el abordaje y el pronóstico de esta patología. Las cajas botín están cada vez más presentes en videojuegos para menores. Se anima a cambiar a línea directa para asegurar el coche eléctrico. Vamos a la piscina, vamos a por un helado. El fin de semana, la mejor variedad musical. Este otoño, en CADENA 100, se refuerzan las defensas de manera natural con HSN. Hay que ...